DK0581882T3 - Fremgangsmåde til screening af plasmaprøver for effektive antistoftitere mod respratoriske viruser - Google Patents

Fremgangsmåde til screening af plasmaprøver for effektive antistoftitere mod respratoriske viruser

Info

Publication number
DK0581882T3
DK0581882T3 DK92912244T DK92912244T DK0581882T3 DK 0581882 T3 DK0581882 T3 DK 0581882T3 DK 92912244 T DK92912244 T DK 92912244T DK 92912244 T DK92912244 T DK 92912244T DK 0581882 T3 DK0581882 T3 DK 0581882T3
Authority
DK
Denmark
Prior art keywords
virus
plasma
plasma samples
antibody titers
cells
Prior art date
Application number
DK92912244T
Other languages
Danish (da)
English (en)
Inventor
George R Siber
Jeanne Leszczynski
Original Assignee
Massachusetts Health Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Health Res filed Critical Massachusetts Health Res
Application granted granted Critical
Publication of DK0581882T3 publication Critical patent/DK0581882T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK92912244T 1991-04-22 1992-04-10 Fremgangsmåde til screening af plasmaprøver for effektive antistoftitere mod respratoriske viruser DK0581882T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68843591A 1991-04-22 1991-04-22
PCT/US1992/002958 WO1992018652A1 (en) 1991-04-22 1992-04-10 Process of screening plasma samples for effective antibody titers against respiratory viruses

Publications (1)

Publication Number Publication Date
DK0581882T3 true DK0581882T3 (da) 1998-09-07

Family

ID=24764406

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92912244T DK0581882T3 (da) 1991-04-22 1992-04-10 Fremgangsmåde til screening af plasmaprøver for effektive antistoftitere mod respratoriske viruser

Country Status (13)

Country Link
US (2) US5412077A (fi)
EP (1) EP0581882B1 (fi)
JP (1) JPH06509866A (fi)
AT (1) ATE161967T1 (fi)
AU (2) AU668092B2 (fi)
CA (1) CA2108259C (fi)
DE (1) DE69223955T2 (fi)
DK (1) DK0581882T3 (fi)
ES (1) ES2113428T3 (fi)
FI (1) FI110723B (fi)
GR (1) GR3026393T3 (fi)
NO (1) NO933697D0 (fi)
WO (1) WO1992018652A1 (fi)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU668092B2 (en) * 1991-04-22 1996-04-26 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
DK1265928T3 (da) * 2000-01-27 2010-11-15 Medimmune Llc RSV-neutraliserende antistoffer med ultra høj affinitet
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20050153382A1 (en) * 2002-06-06 2005-07-14 Chengdu Kuachang Science And Technology Co., Ltd. Biochip kit comprising biochip based on antigen-antibody reactions, and its usage
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
DK3549949T5 (da) 2011-04-22 2024-09-02 Wyeth Llc Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315073A (en) * 1979-10-26 1982-02-09 Cutter Laboratories, Inc. Titration of serum influenza antibody using plaque reduction neutralization test
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4665379A (en) * 1984-05-10 1987-05-12 Anes Electronics, Inc. Vehicle security system
US4665159A (en) * 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4717766A (en) * 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
AU668092B2 (en) * 1991-04-22 1996-04-26 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses

Also Published As

Publication number Publication date
CA2108259C (en) 2003-12-09
EP0581882A4 (en) 1994-06-08
WO1992018652A1 (en) 1992-10-29
FI934657A (fi) 1993-10-21
DE69223955T2 (de) 1998-08-13
EP0581882B1 (en) 1998-01-07
AU680170B2 (en) 1997-07-17
AU6067896A (en) 1996-10-17
US5582827A (en) 1996-12-10
NO933697L (no) 1993-10-14
AU1988592A (en) 1992-11-17
FI934657A0 (fi) 1993-10-21
GR3026393T3 (en) 1998-06-30
ES2113428T3 (es) 1998-05-01
FI110723B (fi) 2003-03-14
US5412077A (en) 1995-05-02
AU668092B2 (en) 1996-04-26
NO933697D0 (no) 1993-10-14
EP0581882A1 (en) 1994-02-09
JPH06509866A (ja) 1994-11-02
DE69223955D1 (de) 1998-02-12
ATE161967T1 (de) 1998-01-15
CA2108259A1 (en) 1992-10-23

Similar Documents

Publication Publication Date Title
DK0581882T3 (da) Fremgangsmåde til screening af plasmaprøver for effektive antistoftitere mod respratoriske viruser
Mann et al. The effect of kaolin on immunoglobulins: an improved technique to remove the nonspecific serum inhibitor of reovirus hemagglutination
FI20021626A (fi) Immuunimäärityksen reagenssi ja menetelmä hepatiitti C-viruksen (HCV) vasta-aineiden havaitsemiseksi
Heberling et al. Rapid dot-immunobinding assay on nitrocellulose for viral antibodies
Pereira et al. Mechanism of hemagglutination by adenovirus types 1, 2, 4, 5 and 6
Baluda Homologous interference by ultraviolet-inactivated Newcastle disease virus
Vejtorp Enzyme‐linked immunosorbent assay for determination of rubella IgG antibodies
ATE202116T1 (de) Antikörperklassenspezifisches entstörungsreagenz
ES8405952A1 (es) Un metodo de detectar un anticuerpo antivirus
Hosoi et al. Heat-labile, complement-like factor (s) of animal sera prevent (s) HIV-1 infectivity in vitro
WO1993025662A3 (en) Replication of hepatitis c virus genome and identification of virus having high infectivity
Leslie et al. Prevalence of hepatitis C antibodies in patients with clotting disorders in Victoria: relationship with other blood borne viruses and liver disease
ES2118129T3 (es) Anticuerpos monoclonales contra las regiones de cubierta putativas del virus vhc y procedimientos de utilizacion de estos.
JPH05184361A (ja) 生物学的に活性なタンパク質の溶液中における低ｐＨでのリン酸トリ−（ｎ−ブチル）の殺ウイルス活性を増強するための使用
FI873233A (fi) Modifierade virala glykoproteiner.
DK162726C (da) Fremgangsmaade til eliminering af falsk positive resultater ved bestemmelse af atl virus-antistof og reagens dertil
ES2132115T3 (es) Anticuerpos monoclonales contra el virus de la hepatitis c y su procedimiento de utilizacion.
Scotti et al. Naturally occurring IgM antibodies to a small RNA insect virus in some mammalian sera in New Zealand
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
MX9203522A (es) Antagonistas de bcrfi para tratar infecciones con virus de epstein-barr.
Siber et al. Effective antibody titers against respiratory viruses
Hoekstra et al. Counter-Immunoelectrophoresis: Rapid Method for Detecting Group-Specific Antigen and Antibodies Associated with Oncogenic Ribonucleic Acid Viruses
SU1467513A1 (ru) Способ определени антигенов вирусов
Yaghoobizadeh et al. Preparation, purification and performance evaluation of polyclonal antibody against SARS-CoV-2 produced in rat
Ho et al. A simple procedure for removing non-specific serum inhibitors of hemagglutination by Japanese encephalitis virus